Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
每年兩次使用 Depemokimab 治療具有嗜酸性表現的重度哮喘。
N Engl J Med 2024-09-09
Depemokimab是一種針對白介素-5的長效生物治療藥物,專為重度哮喘及高嗜酸性白血球計數的患者設計。在第三期臨床試驗中,接受depemokimab的患者在52週內的哮喘惡化年化率顯著低於安慰劑組(SWIFT-1: 0.46 vs. 1.11; SWIFT-2: 0.56 vs. 1.08),顯示出強烈的治療效果(P<0.001)。不過,次要結果如聖喬治呼吸問卷得分並無顯著差異,且兩組的不良事件報告相似。總體而言,depemokimab在減少患者惡化方面顯示療效。此研究由GSK資助,並已在ClinicalTrials.gov註冊。
相關文章PubMedDOI
The global blood donation index: an imperfect measure of transfusion need.
全球血液捐贈指數:一個不完美的輸血需求衡量標準。
Lancet 2024-09-07
Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
光學相干斷層掃描引導與血管造影引導的經皮冠狀動脈介入治療對於複雜病變患者的比較研究 (OCCUPI):一項在南韓進行的研究者主導、多中心、隨機、開放標籤的優越性試驗。
Lancet 2024-09-05
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
藥物塗層球囊血管成形術與救援支架置入對於新發冠狀動脈病變患者的治療(REC-CAGEFREE I):一項開放標籤、隨機、非劣效性試驗。
Lancet 2024-09-05
Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
與心肌梗塞相關的心源性休克中的臨時機械循環支持:隨機試驗的個別患者數據荟萃分析,隨訪6個月。
Lancet 2024-09-05
Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis: The BASIS Randomized Clinical Trial.
顱內動脈狹窄的氣球血管成形術與藥物治療的比較:BASIS 隨機臨床試驗。
JAMA 2024-09-05